文献速递临床试验与 GCP

S-氨氯地平联合氯噻酮对比S-氨氯地平联合替米沙坦治疗氨氯地平单药未达标高血压患者:随机对照试验研究方案

S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-06-20

本研究为前瞻性、随机、双盲、多中心、平行、非劣效性4期试验,计划纳入170例经氨氯地平5mg或S-氨氯地平2.5mg单药治疗≥2周且平均坐位舒张压>90mmHg的高血压患者,随机接受S-氨氯地平2.5mg联合氯噻酮25mg或S-氨氯地平2.5mg联合替米沙坦40mg治疗。主要终点为治疗12周后平均坐位舒张压变化,非劣效界值为3mmHg。

要点

  • 比较CCB+氯噻酮与CCB+ARB在CCB单药未达标患者中的疗效与安全性。
  • 主要终点为12周坐位舒张压变化,非劣效界值3mmHg。
  • 样本量170例,1:1随机,双盲设计。

核心结论

  • 研究旨在证明S-氨氯地平联合氯噻酮在降低舒张压方面非劣效于S-氨氯地平联合替米沙坦,非劣效界值为3mmHg。

研究设计与样本

  • 前瞻性、随机、双盲、多中心、平行、非劣效性4期研究,计划纳入170例患者,1:1随机分组。
  • 纳入经氨氯地平5mg或S-氨氯地平2.5mg单药治疗≥2周且平均坐位舒张压>90mmHg的高血压患者。

关键数值与推荐

  • 主要疗效终点为治疗12周后平均坐位舒张压较基线的变化。
  • 非劣效界值为平均舒张压变化差异3mmHg。
  • 次要终点包括6周舒张压变化、6周和12周坐位收缩压变化、血压达标率(收缩压<140mmHg或舒张压<90mmHg)。

临床怎么用

  • 研究结果可帮助临床医生在CCB单药未达标患者中选择联用氯噻酮或替米沙坦。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of a combination of a calcium channel blocker (CCB) plus chlorthalidone (diuretic) versus a CCB plus an angiotensin receptor blocker (ARB) in patients not responding to CCB monotherapy has not been evaluated previously. We plan to compare the efficacy and safety of S-amlodipine (CCB) plus chlorthalidone versus S-amlodipine plus telmisartan (ARB) combinations among hypertension patients unresponsive to amlodipine monotherapy. METHODS/DESIGN: This study is a prospective, randomized, double-blind, multicenter, parallel, non-inferiority phase 4 study. Hypertension patients who have been treated with amlodipine (5 mg) or S-amlodipine (2.5 mg) monotherapy for ≥2 weeks and whose mean diastolic blood pressure (DBP) is greater than 90 mmHg will be randomized to either S-amlodipine (2.5 mg) plus chlorthalidone (25 mg) or S-amlodipine (2.5 mg) plus telmisartan (40 mg) therapy. The primary efficacy endpoint is mean sitting DBP change after 12 weeks of treatment. The study objective is to prove the non-inferiority of the former combination (test drug) as compared to the latter one (control) with a non-inferiority margin of 3 mmHg in mean DBP change. The secondary endpoints are 6-week DBP change, 6- and 12-week sitting systolic BP (SBP) change, and the attainment of the target BP (SBP < 140 mmHg or DBP < 90 mmHg). Urine albumin, albumin/creatinine ratio (ACR), pulse wave velocity, central BP, 24-h ambulatory BP monitoring, and body fluid composition analysis will be performed at each hospital's discretion. The sample size was estimated as 170 in total with 1:1 randomization. DISCUSSION: This is the first study comparing the efficacy of a CCB plus chlorthalidone versus a CCB plus an ARB in patients who are not responding to CCB single therapy. The study result will help clinicians to choose between chlorthalidone and telmisartan in CCB-unresponsive patients. TRIAL REGISTRATION: ClinicalTrials.gov , NCT03226340. Registered on 2 December 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jo SH, Park SJ, Kim EJ, et al. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29925421. doi:10.1186/s13063-018-2636-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。